Patient Utilization of Opioid Destruction Bags in the Post-op Period
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kristin R Daniel, PharmD
- Phone Number: 402-559-2434
- Email: kdaniel@nebraskamed.com
Study Contact Backup
- Name: Stacie J Ethington, MSN RN
- Phone Number: 402-559-3567
- Email: sethington@nebraskamed.com
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
19 years of age or older Discharging to home and prescribed opioids at discharge post total knee arthroplasty or total hip arthroplasty
Exclusion Criteria:
Under 19 years of age Opioid medication use prior to surgery Not prescribed an opioid to take after discharge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
Control group will receive current standard of care education and surveys at 6-8 weeks post discharge.
|
|
|
Experimental: Intervention
Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
Surveys will be sent to group at 6-8 weeks post discharge.
|
Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Opioid destruction
Time Frame: Six to Eight weeks post discharge
|
Number of patients who report they did or plan to destroy unused opioids
|
Six to Eight weeks post discharge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Education
Time Frame: Six to Eight weeks post discharge
|
Number of patients who recall patient education on storage and disposal of opioid medications at discharge
|
Six to Eight weeks post discharge
|
|
Opioid Storage
Time Frame: Six to Eight weeks post discharge
|
Type of opioid storage method used at home
|
Six to Eight weeks post discharge
|
|
Opioid Destruction Method
Time Frame: Six to Eight weeks post discharge
|
Type of opioid destruction method used or plan to use
|
Six to Eight weeks post discharge
|
|
Leftover Pills
Time Frame: Six to Eight weeks post discharge
|
Estimated number of pills leftover after completion of therapy
|
Six to Eight weeks post discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kristin R Daniel, PharmD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0277-22-EP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.